Sanjivani Parenteral Limited has announced its financial results for the second quarter, revealing a mixed performance with a decline in revenue but maintaining its EBITDA margin.

Revenue and Profit

The pharmaceutical company reported a quarterly revenue of Rs. 155.00 crore, marking a 14.5% year-on-year decline. The company's Profit After Tax (PAT) also decreased by 28.6% year-on-year to Rs. 16.40 crore. Despite the revenue contraction, Sanjivani Parenteral managed to maintain its EBITDA margin at 15.5%.

Segment Performance

The company's performance varied across different segments:

• Injectables Segment: Showed resilience with a 2.4% year-on-year growth.
• Oral Segment: Experienced a significant decline of 35.4% year-on-year, attributed to shipment challenges.

Export Contribution

Exports continued to be a major contributor to Sanjivani Parenteral's business, accounting for 81.6% of the total revenue. The company's core markets include the CIS region, Middle East, Africa, and Latin America.

Financial Highlights

Half-Yearly Performance

For the first half of the current fiscal year, Sanjivani Parenteral reported:

• Total income of Rs. 335.90 crore, down 4.1% from Rs. 350.40 crore in the same period of the previous year.
• PAT of Rs. 33.70 crore, a decrease of 16% compared to Rs. 40.10 crore in the same period last year.

The company's ability to maintain its EBITDA margin at 15.5% despite the revenue decline suggests effective cost management strategies. However, the significant drop in the oral segment's performance due to shipment challenges indicates potential areas for improvement in the company's supply chain and logistics operations.

As Sanjivani Parenteral navigates through these challenges, investors and stakeholders will be keen to see how the company addresses the issues in its oral segment and capitalizes on the growth in its injectables business. The company's strong export presence in key markets may provide a buffer against domestic market fluctuations, but managing shipment challenges will be crucial for future growth.

Sanjivani Parenteral Limited has launched a postal ballot process to seek shareholder approval for the appointment of Mr. Basant Shrivastava as a Non-Executive Independent Director. This move comes as part of the company's efforts to strengthen its board with experienced professionals.

Key Details of the Postal Ballot

About Mr. Basant Shrivastava

Mr. Shrivastava, aged 69, brings over four decades of pharmaceutical industry experience to Sanjivani Parenteral Limited. His expertise lies primarily in sales and marketing, with a career that includes:

• Starting at Johnson & Johnson
• Founding Vita Pharma Agencies
• Current role as Joint Director at Joint Force Pharma Ltd

Additionally, Mr. Shrivastava holds directorships in Panchsheel Organics Limited, where he chairs the Audit Committee and is a member of the Nomination and Remuneration Committee and Stakeholders Relationship Committee.

Voting Process

The company has engaged MUFG Intime India Private Limited (formerly Link Intime India Private Limited) to facilitate the e-voting process. Shareholders whose names appear in the Register of Members or Register of Beneficial Owners as of October 31, 2025 (the cut-off date) are eligible to participate in the e-voting.

Board's Recommendation

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, has proposed this appointment. They have recommended shareholders to approve the resolution for Mr. Shrivastava's appointment as an Ordinary Resolution.

Sanjivani Parenteral Limited's move to appoint Mr. Basant Shrivastava reflects the company's commitment to enhancing its board with experienced professionals from the pharmaceutical industry. Shareholders now have the opportunity to voice their decision through the e-voting process, with the results set to shape the company's leadership structure for the coming years.